PharVision Advisers LLC Invests $259,000 in Privia Health Group, Inc. (NASDAQ:PRVA)

PharVision Advisers LLC bought a new stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 13,231 shares of the company's stock, valued at approximately $259,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. First Horizon Advisors Inc. boosted its holdings in Privia Health Group by 53.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock valued at $35,000 after purchasing an additional 632 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Privia Health Group by 7,833.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock valued at $47,000 after buying an additional 2,350 shares in the last quarter. Quadrant Capital Group LLC grew its position in Privia Health Group by 11.8% in the fourth quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock valued at $95,000 after acquiring an additional 511 shares during the period. Nisa Investment Advisors LLC grew its position in Privia Health Group by 185.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,999 shares of the company's stock valued at $98,000 after acquiring an additional 3,249 shares during the period. Finally, KBC Group NV raised its stake in Privia Health Group by 48.1% during the fourth quarter. KBC Group NV now owns 5,012 shares of the company's stock worth $98,000 after acquiring an additional 1,627 shares in the last quarter. Institutional investors own 94.48% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Piper Sandler upped their target price on shares of Privia Health Group from $25.00 to $40.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Truist Financial raised their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the stock a "buy" rating in a report on Thursday, April 10th. Canaccord Genuity Group boosted their target price on Privia Health Group from $29.00 to $30.00 and gave the stock a "buy" rating in a report on Friday, February 28th. JMP Securities reaffirmed a "market outperform" rating and set a $29.00 price target on shares of Privia Health Group in a report on Monday, April 28th. Finally, Robert W. Baird lifted their price objective on Privia Health Group from $24.00 to $26.00 and gave the company an "outperform" rating in a research report on Tuesday, April 15th. One investment analyst has rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $27.38.

Privia Health Group Stock Performance

NASDAQ PRVA opened at $23.80 on Thursday. The stock has a market capitalization of $2.90 billion, a P/E ratio of 238.02, a price-to-earnings-growth ratio of 3.47 and a beta of 0.87. Privia Health Group, Inc. has a 52 week low of $16.00 and a 52 week high of $26.09. The stock has a fifty day moving average of $23.41 and a 200-day moving average of $22.63.

Insider Activity at Privia Health Group

In related news, CEO Parth Mehrotra sold 13,773 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $24.99, for a total value of $344,187.27. Following the transaction, the chief executive officer now directly owns 423,143 shares in the company, valued at $10,574,343.57. This represents a 3.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO David Mountcastle sold 5,630 shares of Privia Health Group stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total transaction of $125,999.40. Following the sale, the chief financial officer now directly owns 179,676 shares of the company's stock, valued at $4,021,148.88. This represents a 3.04% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,579 shares of company stock worth $1,226,367 over the last 90 days. Insiders own 10.70% of the company's stock.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

Want to see what other hedge funds are holding PRVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Privia Health Group, Inc. (NASDAQ:PRVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.